Angiotensin-Converting Enzyme Inhibitors

"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Descriptor ID	D000806
MeSH Number(s)	D27.505.519.389.745.085
Concept/Terms	Angiotensin-Converting Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Angiotensin Converting Enzyme Inhibitors Inhibitors, Kininase II Kininase II Antagonists Kininase II Inhibitors Angiotensin I-Converting Enzyme Inhibitors Angiotensin I Converting Enzyme Inhibitors Antagonists, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Antagonists, Kininase II Inhibitors, ACE ACE Inhibitors Inhibitors, Angiotensin-Converting Enzyme Enzyme Inhibitors, Angiotensin-Converting Inhibitors, Angiotensin Converting Enzyme Angiotensin-Converting Enzyme Antagonists Angiotensin Converting Enzyme Antagonists Enzyme Antagonists, Angiotensin-Converting

Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Angiotensin-Converting Enzyme Inhibitors [D27.505.519.389.745.085]

Below are MeSH descriptors whose meaning is related to "Angiotensin-Converting Enzyme Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".

Angiotensin-Converting Enzyme Inhibitors
Vasopeptidase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.

Bar chart showing 90 publications over 27 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	1	2
1997	2	0	2
1998	1	1	2
1999	0	1	1
2000	2	1	3
2002	2	1	3
2003	1	4	5
2004	1	3	4
2005	2	2	4
2006	3	2	5
2007	4	1	5
2008	3	3	6
2009	2	1	3
2010	0	5	5
2011	1	2	3
2012	1	1	2
2013	2	1	3
2014	3	1	4
2015	1	2	3
2016	2	3	5
2017	2	1	3
2018	0	2	2
2019	0	2	2
2020	2	1	3
2021	2	3	5
2022	1	3	4
2023	0	1	1

Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.

Rist A, Sevre K, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. The current best drug treatment for hypertensive heart failure with preserved ejection fraction. Eur J Intern Med. 2024 Feb; 120:3-10.

View in: PubMed
Ferreira JP, Konstam M, Rossignol P, Kiernan MS, Zannad F. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL. J Card Fail. 2023 01; 29(1):45-52.

View in: PubMed
Tisminetzky M, Gurwitz JH, Tabada G, Reynolds K, Fortmann SP, Garcia E, Pham T, Goldberg R, Go AS. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.

View in: PubMed
Gupta N, Settle L, Brown BR, Armaignac DL, Baram M, Perkins NE, Kaufman M, Melamed RR, Christie AB, Danesh VC, Denson JL, Cheruku SR, Boman K, Bansal V, Kumar VK, Walkey AJ, Domecq JP, Kashyap R, Aston CE. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med. 2022 10 01; 50(10):e744-e758.

View in: PubMed
Keith SW, Maio V, Arafat HA, Alcusky M, Karagiannis T, Rabinowitz C, Lavu H, Louis DZ. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. BMC Cancer. 2022 Feb 07; 22(1):150.

View in: PubMed
Rattanapunya S, Deethae A, Woskie S, Kongthip P, Matthews KR. Occurrence of Antibiotic-Resistant Staphylococcus spp. in Orange Orchards in Thailand. Int J Environ Res Public Health. 2021 12 27; 19(1).

View in: PubMed
Brinkley DM, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021 12; 40(12):1605-1613.

View in: PubMed
Dillon GA, Stanhewicz AE, Serviente C, Greaney JL, Alexander LM. Hydrogen sulfide-dependent microvascular vasodilation is improved following chronic sulfhydryl-donating antihypertensive pharmacotherapy in adults with hypertension. Am J Physiol Heart Circ Physiol. 2021 10 01; 321(4):H728-H734.

View in: PubMed
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.

View in: PubMed
Moore E, Reynolds JA, Davidson A, Gallucci S, Morel L, Rao DA, Young HA, Putterman C. Promise and complexity of lupus mouse models. Nat Immunol. 2021 06; 22(6):683-686.

View in: PubMed

People

Explore

Similar Concepts

Top Journals